Frequently Asked Questions
Factors such as increasing awareness of healthcare infrastructure, huge number of pipeline studies and availability of advanced treatment procedures are acting as the major drivers for the global primary biliary cirrhosis market.
The segments covered are Drug Type (Ursodeoxycholic acid (USDA), Obeticholic acid), Stages (Portal, Periportal, Septal, Cirrhotic, Others), Treatment Indication (Cirrhosis, Itching, Dry Eye, Dry Mouth, Others), Treatment Type (Medication, Surgery, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
North America is dominating the market due to increased investment by pharmaceutical industries for the advancement in the treatment and favourable reimbursement scenario.
The top players in the market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Glenmark Pharmaceuticals Inc (India), Amneal Pharmaceuticals LLC. (U.K.), Intercept Pharmaceuticals, Inc (U.K.), Emcure Pharmaceuticals Limited(India), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd (Israel)
